South Africa's HIV Vaccine Breakthrough Stalled as US Funding Freeze Halts Critical Research
Healthy
JOHANNESBURG — In a high-tech Johannesburg laboratory, Nozipho Mlotshwa and her team were on the verge of a potential breakthrough in the decades-long quest for an HIV vaccine. Their latest formulation had just triggered promising immune responses in animal trials when an abrupt order from Washington froze all progress.
The 32-year-old lab technician still remembers the excitement as their mRNA-based vaccine prototypes showed early success. "We were gaining real momentum," Mlotshwa recalls, standing beside freezers now storing abandoned blood samples at Wits University's Antiviral Gene Therapy Research Unit. But that optimism shattered when USAID - their sole funding source - suspended its $45 million grant under new White House directives.
This sudden halt affects not just Mlotshwa's preclinical work but also derails human trials scheduled across three African nations for another promising candidate. Both projects formed key pillars of BRILLIANT, Africa's first continent-led HIV vaccine initiative aimed at building local research capacity while tackling a virus that infects over 8 million South Africans.
A Scientific Dream Deferred
"It feels like watching a house you built with care being demolished," says Dr. Nigel Garrett of the Desmond Tutu Health Foundation, one of BRILLIANT's lead partners. His team had spent years preparing to test an innovative dual-vaccine combination from US and Dutch developers - now indefinitely shelved alongside imported medical supplies.
The Johannesburg researchers were pioneering a unique approach using genetic material from rare South African patients whose immune systems naturally neutralize HIV. By harnessing mRNA technology (the same platform behind COVID-19 vaccines), they hoped to replicate this biological advantage at scale.
Global Ripple Effects
President Trump's January executive order freezing foreign aid for policy review has stranded humanitarian projects worldwide, from agricultural protections to epidemic response teams. A separate directive specifically targeting South Africa cites disagreements over land reform and international legal actions.
"A HIV vaccine remains the holy grail of our field," emphasizes Professor Patrick Arbuthnot, director of Wits' gene therapy unit where temperatures are carefully maintained to preserve paused experiments should funding resume.
